Australian company Telix has announced that it will supply ILLUCIX for a Phase 3 study investigating the efficacy of Bayer's PBS-listed NUBEQA (darolutamide) plus androgen deprivation therapy in hormone-sensitive prostate cancer. …
Australian company to supply Bayer with Illuccix for prostate cancer study
May 9, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News -
Brandon BioCatalyst welcomes the inclusion of its CUREator in new program
July 16, 2025 - - Australian Biotech -
Cancer Australia launches research program targeting early-onset cancers
July 16, 2025 - - Latest News -
Imugene completes significant placement and launches share purchase plan
July 16, 2025 - - Australian Biotech